Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL442570 | 0.91 | USP2 (0.40) | NR1H2GRIN2BGRIN2CCHRM2CHRM1 | |
| SCHEMBL27092800 | 0.85 | GRIN2B (0.39) | NR1H2GRIN2BGRIN2CHPGDSMN1; SMN2 | |
| SCHEMBL25255216 | 0.83 | GRIN2B (0.38) | GRIN2BGRIN2CHPGDSMN1; SMN2CTSK | |
| SCHEMBL444287 | 0.82 | GRIN2B (0.37) | GRIN2BGRIN2CHPGDSMN1; SMN2CTSK | |
| SCHEMBL27219428 | 0.82 | GRIN2B (0.37) | GRIN2BGRIN2CHPGDSMN1; SMN2CNR2 | |
| SCHEMBL26915825 | 0.82 | GRIN2B (0.37) | GRIN2BGRIN2CHPGDSMN1; SMN2CNR2 | |
| SCHEMBL27219105 | 0.81 | GRIN2B (0.37) | GRIN2BGRIN2CHPGDSMN1; SMN2CTSK | |
| SCHEMBL442706 | 0.81 | GRIN2B (0.37) | GRIN2BGRIN2CHPGDSMN1; SMN2CNR2 | |
| SCHEMBL444199 | 0.81 | GRIN2B (0.41) | GRIN2BGRIN2CHPGDSMN1; SMN2CTSK | |
| SCHEMBL26915933 | 0.81 | GRIN2B (0.37) | GRIN2BGRIN2CHPGDSMN1; SMN2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2684871-B1 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives | HOFFMANN LA ROCHE (CH) | 2016-05-04 | — | — | EP | disclosed |
| EP-2684871-A1 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives | F. Hoffmann-La Roche AG (CH) | 2014-01-15 | — | — | EP | disclosed |
| EP-2280970-B1 | IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8513425-B2 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2354124-B1 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives | HOFFMANN LA ROCHE (CH) | 2013-02-13 | — | — | EP | disclosed |
| US-20120065225-A1 | HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES AND USES THEREOF | IYER PRAVIN (US) | 2012-03-15 | — | — | US | disclosed |
| US-8124636-B2 | Imidazolidinone derivatives as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8084623-B2 | heterocyclic ketones such as (3-Benzyl-pyrrolidin-3-yl)-(1H-indol-5-yl)-methanone, used as antidepressants or anxiolytic agents | ROCHE PALO ALTO LLC (US) | 2011-12-27 | — | — | US | disclosed |
| EP-2354124-A2 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives | F. Hoffmann-La Roche AG (CH) | 2011-08-10 | — | — | EP | disclosed |
| EP-2102157-B1 | HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-06-22 | — | — | EP | disclosed |
| EP-2297096-A2 | ARYL KETONE AS MRI | F. Hoffmann-La Roche AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| EP-2280970-A1 | IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-02-09 | — | — | EP | disclosed |
| US-20090318493-A1 | Aryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
| WO-2009153178-A2 | ARYL KETONE AS MRI | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009132986-A1 | IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| US-20090275573-A1 | Imidazolidinone Derivatives as 11B-HSD1 Inhibitors | HOFFMANN-LA ROCHE, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20080146607-A1 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065225-A1 | HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES AND USES THEREOF | CNKSR1, RB1, AR | NR1H2 404/4885GRIN2B 1547/4885GRIN2C 838/4885 |
| US-20080146607-A1 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | CNKSR1, RB1, AR | NR1H2 404/4885GRIN2B 1547/4885GRIN2C 838/4885 |
| US-20090275573-A1 | Imidazolidinone Derivatives as 11B-HSD1 Inhibitors | HSD11B1, HSD17B1, HSD17B11 | NR1H2 138/4885GRIN2B 872/4885GRIN2C 1124/4885 |
| US-20090318493-A1 | Aryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | TPH2, TPH1, ADRA2C | NR1H2 1448/4885GRIN2B 207/4885GRIN2C 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.